Showing 1 - 9 results of 9 for search 'Carlos Gomez-Roca', query time: 0.04s Refine Results
  1. 1
    Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

    Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas? by Jonathan Khalifa, Jonathan Khalifa, Julien Mazieres, Julien Mazieres, Carlos Gomez-Roca, Carlos Gomez-Roca, Maha Ayyoub, Maha Ayyoub, Elizabeth Cohen-Jonathan Moyal, Elizabeth Cohen-Jonathan Moyal, Elizabeth Cohen-Jonathan Moyal

    Published 2021-04-01
    Get full text
    Article
  2. 2
    315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody

    315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody by Aurélien Marabelle, Carlos Gomez-Roca, Pierre Ferre, Eric Chetaille, Aurelie Petain, Celine Thuilliez, Isabelle Vandenberghe, Francisco Cruzalegui, Asmaa Boudribila, Mariya Pavlyuk

    Published 2020-11-01
    Article
  3. 3
    1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies

    1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and RE... by Kohei Shitara, Antoine Adenis, Antoine Hollebecque, Antoine Italiano, Shohei Koyama, Hiroyoshi Nishikawa, Carlos Gomez-Roca, Philippe Cassier, Alban Bessede, Jean-Philippe Metges, Sophie Cousin, Jean-Philippe Guégan, Shota Fukuoka, Lola-Jade Palmieri

    Published 2023-11-01
    Article
  4. 4
    Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade

    Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade by Carlos Martinez-Gomez, Marie Michelas, Clara-Maria Scarlata, Anna Salvioni, Carlos Gomez-Roca, Victor Sarradin, Françoise Lauzéral-Vizcaino, Virginie Féliu, Agnès Dupret-Bories, Gwénaël Ferron, Jérôme Sarini, Christel Devaud, Jean-Pierre Delord, Camille-Charlotte Balança, Alejandra Martinez, Maha Ayyoub

    Published 2022-07-01
    Get full text
    Article
  5. 5
    721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors

    721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumor... by Anne Goubier, Neeltje Steeghs, Carlos Gomez-Roca, Philippe Cassier, Elena Fernandez, Eelke Gort, Hilde De Winter, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson, Vladimir Kirkin, Philippe Legenne

    Published 2023-11-01
    Article
  6. 6
    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

    Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. by Bert H O'Neil, John M Wallmark, David Lorente, Elena Elez, Judith Raimbourg, Carlos Gomez-Roca, Samuel Ejadi, Sarina A Piha-Paul, Mark N Stein, Albiruni R Abdul Razak, Katia Dotti, Armando Santoro, Roger B Cohen, Marlena Gould, Sanatan Saraf, Karen Stein, Sae-Won Han

    Published 2017-01-01
    Get full text
    Article
  7. 7
    PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells

    PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells by Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub

    Published 2021-01-01
    Get full text
    Article
  8. 8
    Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort

    Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort by Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle De La Fouchardière, François Bertucci, Anthony Gonçalves, Carlos Gomez-Roca, Benoit You, Valéry Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Séverine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenaël Garin, Jean-Yves Blay, David Pérol

    Published 2023-06-01
    Get full text
    Article
  9. 9
    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging

    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simulta... by Anne Laprie, Soléakhéna Ken, Thomas Filleron, Vincent Lubrano, Laure Vieillevigne, Fatima Tensaouti, Isabelle Catalaa, Sergio Boetto, Jonathan Khalifa, Justine Attal, Guillaume Peyraga, Carlos Gomez-Roca, Emmanuelle Uro-Coste, Georges Noel, Gilles Truc, Marie-Pierre Sunyach, Nicolas Magné, Marie Charissoux, Stéphane Supiot, Valérie Bernier, Muriel Mounier, Muriel Poublanc, Amandine Fabre, Jean-Pierre Delord, Elizabeth Cohen-Jonathan Moyal

    Published 2019-02-01
    Get full text
    Article

Search Tools: